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Abstract Flow cytometry (FCM) is widely used in can-
cer research for diagnosis, detection of minimal residual
disease, as well as immune monitoring and profiling fol-
lowing immunotherapy. In all these applications, the
challenge is to detect extremely rare cell subsets while
avoiding spurious positive events. To achieve this objec-
tive, it helps to be able to analyze FCM data using multiple
markers simultaneously, since the additional information
provided often helps to minimize the number of false
positive and false negative events, hence increasing both
sensitivity and specificity. However, with manual gating, at
most two markers can be examined in a single dot plot, and
a sequential strategy is often used. As the sequential
strategy discards events that fall outside preceding gates at
each stage, the effectiveness of the strategy is difficult to
evaluate without laborious and painstaking back-gating.
Model-based analysis is a promising computational tech-
nique that works using information from all marker
dimensions simultaneously, and offers an alternative
approach to flow analysis that can usefully complement
manual gating in the design of optimal gating strategies.
Results from model-based analysis will be illustrated with
examples from FCM assays commonly used in cancer
immunotherapy laboratories.
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Flow cytometry in immune monitoring for cancer
immunotherapy
Flow cytometry (FCM) is one of the older high throughput
techniques, and as such has become an integral tool in
immune monitoring. In FCM, cells in a fluid medium are
streamed in a single file through a capillary tube, and light
from several lasers is directed at each individual cell as it
passes through. Typically, each cell is labeled with different
fluorescent dyes attached to monoclonal antibodies that
recognize specific cellular markers that may be cell surface
or intracellular proteins. Laser light hitting each cell results in
scatter and activation of the fluorescent dyes bound to the
cell. The light from forward and side scatter are detected
electronically in separate channels, as is the light emitted by
each fluorescent dye molecule as it relaxes from its activated
state. Since each monoclonal antibody of a given specificity
is bound to a different fluorescent dye, the amount of light in
each wavelength detected will be directly proportional to the
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number of bound antibodies of that specificity, and therefore
a measure of the density of the cellular marker targeted by
that monoclonal antibody on each cell [1].
Flow cytometry assays therefore provide the ability to
measure cellular marker levels for individual cells. With
flow rates of hundreds to thousands of cells per second, FCM
also captures cellular population statistics in a single assay.
FCM can thus measure both the phenotype and function of
specific cell subtypes in a sample that may contain many
different cell subtypes, unlike assays like microarrays and
proteomics that measure aggregate features of the entire
mixture of cells. This ability of FCM to identify and char-
acterize rare cell subsets is particularly critical in monitoring
the immune response following cancer immunotherapy and
detection of minimal residual disease (MRD), where the cells
of interest typically constitute much less than 1% of the total
immune cells in the peripheral blood. In this review, we will
use the context of immune monitoring for cancer immuno-
therapy for illustration, but the methods discussed should be
widely applicable. In particular, our examples will focus on
the tracking of antigen-specific lymphocytes by T cell
receptor binding to specific fluorescence labeled peptide-
MHC tetramers, as well as intracellular staining (ICS) and
proliferation assays for functional readouts.
Challenges to manual analysis
For multi-center clinical trials, the ability to obtain repro-
ducible and consistent results from FCM across different
institutions is obviously critical. Consequently, there is a long
history, spanning at least two decades, of efforts to enable
robust and accurate enumeration of lymphocyte subsets, and
in particular, to achieve the optimal balance of recovery of
the populations of interest with minimal contamination from
other cell subsets or debris. These efforts include the use of
backgating for measuring purity and recovery combined with
checksums [2], use of CD45 in three-color and four-color
assays [3, 4], use of a single platform technology for absolute
counts [5, 6], panleukogating [7] and the use of pre- aliquoted
lyophilized reagents [8].
Throughout these studies, it has been recognized that
different gating methods across institutions are a known
major source of assay variability and that standardized
analytical strategies improve both intra- and inter-laboratory
variability [9]. In particular, the study by Maecker et al. [8]
highlighted the contribution of gating as a major source
of variability in a multi-center study of multi-parameter
ICS assays. With the advent of polychromatic FCM tech-
nology [10], issues of standardization and variability due to
gating techniques become even more acute, due to the
exponential increase in analytical complexity with each
marker added [11].
In traditional gating-based analysis, expert-defined
boundaries are used to identify flow event subsets of
interest [11–14]. Because gating is performed manually
based on visual comparison with controls, such boundaries
are constrained to be in one or two dimensions only, and a
sequence of gates must be used to analyze multi-dimensional
data sets. Limitations of software based on the gating concept
are:
1. Gating is expert-driven and different operators often
disagree on the ideal gating strategy for a given panel
2. Even with a common gating strategy, gating is difficult
to replicate across different instruments and institu-
tions [7, 8, 15, 16]
3. Gating is a one- to two-dimensional procedure and
difficult to scale to multi-parameter data sets
4. Gating per se provides no guidance on the subsequent
interpretation of the clinical relevance for the cell
subsets found.
Because of these issues, it is highly beneficial for centers
performing immunotherapy research for cancer to partici-
pate in proficiency testing, so that feedback on their per-
formance relative to other clinical laboratories can be
assessed. In the field of cancer vaccines, leadership in
administering these proficiency tests is provided by the
Cancer Immunotherapy Consortium (CIC) ImmunoAssay
Working Group (IAWG) and the Cancer Immunoguiding
Program (CIP) of the Cancer Immunotherapy Association
(CIMT). These groups offer proficiency testing for
ELISPOT as well as ICS and tetramer-based FCM assays,
and have achieved significant gains in assay harmonization
and improvement across multiple laboratories in a short
time period [17–20].
Classification via flow should be objective and repro-
ducible. Even when using a common gating strategy,
achieving consistent and reproducible results requires a
significant investment of time and training of not only gate
placement but also protocols for preparing samples, and
participation in group standardization/proficiency testing
efforts. Where standard protocols do not exist (e.g. regu-
latory T cells), individual laboratories have to design their
own gating strategies to identify the target cell subsets. In
any event, achieving replicable results when the events of
interest are exceptionally rare demands careful attention to
potential false negatives and false positives, and the design
of strategies to minimize them as much as possible.
Model-based analysis
Model-based analysis is an exciting alternative and sup-
plement to gating-based analysis. In model-based analysis,
flow event subsets are clustered by a data-driven algorithm
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and used to construct a generative probability model. Data
fitting can be naturally performed in the full dimensionality
of the data set, and hence scales well to high-dimensional
data sets. In addition, expert input is not necessary for the
analysis, removing the subjectivity inherent in gating-based
approaches. In particular, because the modeling approach
uses information from all markers simultaneously rather
than pair-wise as in manual gating, it can often identify
false negative and false positive events that are not easily
discriminated in any two-dimensional projection. Model-
based analysis therefore provides an objective, reproduc-
ible and scalable approach that directly addresses many of
the limitations of gating-based analysis, and is hence under
active investigation by several research groups [21–24].
Our approach to model-based analysis is based on the
use of statistical mixture models [22, 25]. Statistical mix-
ture models are very widely used in scientific problems
where objects represented in several or many dimensions
are to be clustered or classified. One appeal of mixture
models is the ability to represent essentially any observed
data distribution to a high degree of accuracy [26, 27]. In
particular, mixture models have recently been demon-
strated to be effective at identifying lymphocyte cell sub-
sets from FCM data [22–24].
There has recently been renewed interest in the use of
statistical mixture models for cell subset identification [21–
24], including work by our group. Boedingheimer and
Ferbas use a fixed component size mixture of Gaussians
and an expectation maximization (EM) algorithm to iden-
tify differences in circulating B cells between normal
donors and systemic lupus erythematosus (SLE) patients
[21]. Lo et al. [23] also use an EM algorithm and fixed
component size mixtures of Gaussian or t distributions to
identify CD3?CD8? cells in a graft-versus-host disease
(GvHD) data set. Pyne et al. [24] use a finite mixture of
skew and heavy-tailed multivariate distributions fitted with
an EM algorithm and validated the approach on lympho-
blastic cell lines and regulatory T cells. This recent work
has clearly confirmed the validity and usefulness of a sta-
tistical mixture modeling approach for cell subset identi-
fication with FCM data. On a technical front, we have
recently implemented mixture model algorithms that are
optimized for massively parallel yet highly affordable
graphics processing units (GPU) for speed-ups of two
orders of magnitude, enabling the analysis of even massive
data sets [28].
To fit an arbitrary n-dimensional flow data set, we
require a flexible yet tractable probability model. One
popular approach is to use a large number of well-
understood multivariate normal distributions to build a
complex and multi-modal distribution (see Fig. 1). With a
sufficient number of normal components, such mixtures
can fit any distribution arbitrarily well. With non-parametric
mixture models, the number of mixture components needed
for fitting can be directly estimated from the data itself,
hence providing an automatic and objective basis for model
fitting.
For interpretation of the model, however, we typically
want to be able to quantify distinct cell subsets of interest.
Because cell subsets may be asymmetric, they typically
correspond to more than one normal component. We
therefore require a way to merge normal components into
clusters in such a way that each cluster corresponds to a
distinct cell subset. One simple way to achieve this is to
identify cell subsets with modes (peaks), and cluster all
components that share the same mode as a single cell
subset. Alternatively, the model can be specified as a
mixture of mixtures, where the concept of a cell subset as
comprising one or more normal components is directly
built into the model [22].
Examples from tetramer, ICS and CFSE assays
We illustrate with an example using such mixture models
to identify events positive for cytokine expression in an
ICS assay, and how this approach can reduce false negative
and positive events resulting in greater sensitivity and
specificity (Fig. 2). A similar approach can be used to
identify tetramer positive events (Fig. 3) and the charac-
teristics of dividing and non-dividing lymphocytes in a
CFSE assay (Fig. 4). These examples clearly show that
model-based analysis provides new relevant information
that can be used to improve gating strategies. Since mixture
models identify cell subsets using all markers simulta-
neously, they more easily overcome issues from non-specific
binding, such as binding to Fc receptors on macrophages or
monocytes. As cells that bind non-specifically fall out as a
Fig. 1 A mixture model is comprised of multiple simpler distribu-
tions added together to describe a more complex distribution. In this
way, with a sufficient number of simple components (typically
multivariate normal distributions), arbitrarily complex distributions
can be fitted to flow cytometry data
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Fig. 2 Mixture models reveal potential false negatives and false
positives in an ICS assay. The left set of panels show ICS-positive
events (small arrows) that are CD3?CD4? or CD3?CD8? but have
atypical FSC/SSC characteristics possibly due to their state of
activation that will be false negatives with a standard gating strategy.
The middle panel shows a diagonal streak (large arrow) from
non-specific binding due to dead cells. As this is classified as a
separate cluster, it is trivial to eliminate such false positives with
model-based analysis, but is otherwise extremely challenging with
manual analysis. Right set of panels shows the relative frequency of
ICS positive CD4? and CD8? cells obtained with manual analysis
and automated clustering
Fig. 3 Identification of tetramer-binding CD4-CD8? cells with
model-based analysis. Data are from an unpublished immune
monitoring study of a multi-peptide vaccination trial designed for
HLA-A2 patients with biochemical relapse after prostatectomy. The
figure shows the frequency of cells binding to HLA-A2 tetramers
(relative to CD4-CD8? cells) constructed using an epitope derived
from the prostate specific membrane antigen PSMA 711-719
ALFDIESKV before (top panel) and after (bottom panel) four
vaccinations in one patient. Cells in both panels were expanded in
vitro in the presence of the specific peptide and interleukins before
staining. Background events are gray, CD4-CD8? events are yellow
and events from CD4-CD8? tetramer? are brown. Clusters were
defined against the mean (l) and standard deviations (SD) of all
events from the before vaccination panel as follows: clusters were
designated as CD4- if the mean CD4 of the cluster was less than
l-SD, CD8? if the mean CD8 of the cluster was greater than l ? SD,
and tetramer? if the mean tetramer of the cluster was greater than
l ? 3 SD
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separate cluster with multi-dimensional analysis, they are
easily identified and can be removed from analysis (Fig. 2).
However, because these non-specific events often fall in
regions of interest, to find and exclude this cell subset
manually generally requires a significant amount of time
spent back-gating, looking where events in a region fall on
other projections, or inclusion of more markers in the
panel, such as viability dyes or dump channels. In addition,
model-based analysis can identify potential cells of interest
that are easily missed with manual gating, such as the ICS-
positive CD4? and CD8? events in Fig. 2. Because of
their atypical FSC and SSC characteristics, possibly due to
their state of activation, they would be excluded in a
standard gating strategy. While non-specific binding to Fc
receptors on cell types such as macrophages and mono-
cytes cannot be excluded, we believe that these
CD3?CD4? and CD3?CD8? events may well be
‘‘blasting’’ lymphocytes. The ability to automatically find
such cells enables model-based analysis to have improved
sensitivity and specificity compared to manual analysis
[22].
The mapping of modal clusters to cell subsets of interest
is done by examining the statistical properties of each
cluster. In Fig. 3, model-based analysis was applied to
identify tetramer positive clusters using ongoing, still
unpublished immune monitoring data from a novel multi-
peptide vaccine study [29]. Data samples pre-vaccination
were used as the negative control, and CD4-CD8?
tetramer? clusters were identified from digitally concate-
nated data from PBMC taken before and after vaccination
and expanded in vitro. Based on information from the
negative control, two other heuristic criteria were also
applied—the corresponding tetramer cluster in the negative
control should have very few events, and the sample tet-
ramer cluster should be significantly over-represented, over
three fold with respect to the negative control. Once target
clusters are identified, dot plots of the clusters in distinct
colors are evaluated on all pair-wise marker combinations
of scatters and markers, and reviewed by an experienced
flow cytometrist. In Fig. 4, a model was fit to a CFSE
assay. When looking at the FSC and SSC of clusters
believed to correspond to proliferating CD4? and CD8? T
cells it can be seen that the FSC and SSC of many pro-
liferating cells would not fall within a standard ‘‘tight’’
lymphocyte gate and may be missed by an untrained eye
using traditional gate based analysis, suggesting that
model-based analysis may be more robust in some cases,
especially for novel panels or atypical cell subsets.
In addition to cell subset identification, model-based
approaches can also be used to quantify the uncertainty of
any statistical inference made, as well as extract additional
useful information from the fitted probability model. For
example, fitted probability models may provide informa-
tion on how to set a positivity threshold. Having fitted a
probability model to the negative control, we can simulate
many random draws from the fitted model, and hence
determine a positivity threshold at any significance level
desired. We are currently developing information measures
based on the fitted model that tell us how much a given
marker contributes to the identification of a specified cell
subset, providing useful information to optimize panel
design and gating strategy.
The high-dimensional future of flow cytometry
The latest generation of flow cytometers can resolve
approximately 20 different colors [10]. This means that up
to 20 different markers can be used to characterize the cells
in a sample, and high-throughput setups with 96- or 384-
well plates will generate large numbers of data sets, each
potentially comprising 1–2 million events in 10–20
Fig. 4 Traditional small, tight lymphocyte gates will exclude most
dividing lymphocytes in a CFSE assay. Viable (amine low)
CD3?CD4? and CD3?CD8? lymphocyte clusters are plotted to
illustrate that proliferating CFSE-low cells (red) have highly atypical
scatter characteristics and are likely to be excluded using standard
‘‘lymphocyte’’ gating strategies that are effective for non-proliferating
lymphocytes (orange)
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dimensions. Further increases in the number of markers
that can be used in a single blood sample are currently
limited by spectral emission overlap between different
fluorochromes that reduces sensitivity.
While state-of-the-art FCM data samples are already of
moderately high dimensionality, further increasing FCM
resolution will allow substantial scientific and medical
advances, including:
1. Better discrimination of immune cell types on the basis
of multiple activation, maturation, regulation, prolif-
eration, and functional marker expression, increasing
the likelihood of discovering biomarkers or flow
cytometric signatures that correlate well with disease
or vaccination outcomes;
2. Screening of more peptide-MHC multimers for anti-
gen-specific T cell populations in order to identify
potential epitope targets for immunotherapy with
fewer blood samples; and
3. Better reconstruction of the kinetics of intracellular
signaling with antibodies targeting phosphorylation
sites of more proteins within signaling cascades.
Two major recent technological advances offer the
potential to greatly increase the resolution of FCM. The
first replaces fluorochrome dyes with stable isotope metal
atoms as reporter tags, hence removing the problem of
emission overlap [30]. Unlike traditional FCM, marker
densities are evaluated by single cell mass spectrometry,
hence ruling out live cell sorting applications. However,
the resolution of individual reporter tags is greatly
increased with this technology due to the lack of spectral
overlap, and it is estimated that 60–100 markers are fea-
sible. While this inductively coupled plasma mass spec-
trometry (ICP-MS) technology is relatively new,
commercially available cytometers (CyTOF) and reagents
(MAXPAR) have been manufactured by DVS Sciences
(http://www.dvssciences.com).
The other major advance exploits combinatorial
encoding of reporter tags to vastly increase the resolution
of different cell subsets with a fixed number of markers
[31, 32]. The basic idea is to use k colors to identify a
single marker—in principle, if we can decode the color
combinations efficiently, we can resolve n choose k dif-
ferent markers with n total colors and a k color per marker
encoding. This dramatically increases the resolution of
FCM—for example, the theoretical maximum number of
different markers in a single blood sample that can be
resolved with n = 11 and k = 2 is 55, rising with n = 18
and k = 9 to 48,620!
We have shown that modeling approaches to FCM
analysis can help reduce false positive and false negative
events, and hence contribute to the robust identification of
very rare cell subsets critical in MRD and immune
monitoring applications in cancer research. It is critical that
such tools are properly validated before large-scale use,
and we are currently working with the Cancer Immuno-
guiding Program (CIP) to compare manual and clustering
methods for identifying tetramer positive cells. We have
also recently been funded to validate model-based
approaches for ICS FCM in collaboration with the Cancer
Immunotherapy Consortium (CIC).
In the highly multiplexed future of FCM, such tools for
efficient high-dimensional multivariate analysis of FCM data
will become increasingly more essential. While in the past
model-based analysis was slow, the ever increasing power of
computers, including the use of general purpose GPU com-
puting technologies that we have developed for FCM [28],
are removing this limitation. We anticipate that software
based on model-based analysis has the very real possibility of
eventually displacing gating-based analysis software, due to
improvements in sensitivity and specificity as well as the
scalability, objectivity and automation brought by model-
based analysis. This is especially true for the analysis of the
high-volume, high-dimensional and multiplexed data sets
that are increasingly important for identifying immunother-
apeutic targets and for discovering immune correlates of
vaccine efficacy or disease outcome in cancer patients.
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